Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dewpoint Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available.
At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
ECOG performance status of 0 or 1.
Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy.
Age ≥18 years (or ≥ age of majority per local regulation)
Life expectancy ≥3 months
Willing and able to comply with protocol requirements
You may not be if
Symptomatic or uncontrolled brain metastasis requiring concurrent treatment,
Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.).
Inadequate organ function
Known hypersensitivity to study drug or excipients
Clareo Health | DPTX3186 in Wnt Pathway Activated Solid Tumors
